These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 32470492)

  • 61. Canagliflozin and cardiovascular and renal events in type 2 diabetes.
    Guthrie R
    Postgrad Med; 2018 Mar; 130(2):149-153. PubMed ID: 29297732
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial.
    Cherney DZI; Zinman B; Inzucchi SE; Koitka-Weber A; Mattheus M; von Eynatten M; Wanner C
    Lancet Diabetes Endocrinol; 2017 Aug; 5(8):610-621. PubMed ID: 28666775
    [TBL] [Abstract][Full Text] [Related]  

  • 63. SGLT2 Inhibition for CKD and Cardiovascular Disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney Foundation.
    Tuttle KR; Brosius FC; Cavender MA; Fioretto P; Fowler KJ; Heerspink HJL; Manley T; McGuire DK; Molitch ME; Mottl AK; Perreault L; Rosas SE; Rossing P; Sola L; Vallon V; Wanner C; Perkovic V
    Am J Kidney Dis; 2021 Jan; 77(1):94-109. PubMed ID: 33121838
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Fracture Risk After Initiation of Use of Canagliflozin: A Cohort Study.
    Fralick M; Kim SC; Schneeweiss S; Kim D; Redelmeier DA; Patorno E
    Ann Intern Med; 2019 Feb; 170(3):155-163. PubMed ID: 30597484
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Acute pancreatitis risk in type 2 diabetes patients treated with canagliflozin versus other antihyperglycemic agents: an observational claims database study.
    Yuan Z; DeFalco F; Wang L; Hester L; Weaver J; Swerdel JN; Freedman A; Ryan P; Schuemie M; Qiu R; Yee J; Meininger G; Berlin JA; Rosenthal N
    Curr Med Res Opin; 2020 Jul; 36(7):1117-1124. PubMed ID: 32338068
    [No Abstract]   [Full Text] [Related]  

  • 66. [Severe diabetic ketoacidosis, acute kidney injury and dehydration due to canagliflozin in type 2 diabetes mellitus patient: Atypical clinical presentation].
    Moreno Obregón F; Espino Montoro A; Marín Martín J; León Jiménez D
    Aten Primaria; 2019 Dec; 51(10):664-666. PubMed ID: 31326123
    [No Abstract]   [Full Text] [Related]  

  • 67. Effects of canagliflozin on cardiovascular, renal, and safety outcomes in participants with type 2 diabetes and chronic kidney disease according to history of heart failure: Results from the CREDENCE trial.
    Sarraju A; Li J; Cannon CP; Chang TI; Agarwal R; Bakris G; Charytan DM; de Zeeuw D; Greene T; Heerspink HJL; Levin A; Neal B; Pollock C; Wheeler DC; Yavin Y; Zhang H; Zinman B; Perkovic V; Jardine M; Mahaffey KW
    Am Heart J; 2021 Mar; 233():141-148. PubMed ID: 33358942
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Effects of Canagliflozin on Fracture Risk in Patients With Type 2 Diabetes Mellitus.
    Watts NB; Bilezikian JP; Usiskin K; Edwards R; Desai M; Law G; Meininger G
    J Clin Endocrinol Metab; 2016 Jan; 101(1):157-66. PubMed ID: 26580237
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Intra- and inter-subject variability for increases in serum ketone bodies in patients with type 2 diabetes treated with the sodium glucose co-transporter 2 inhibitor canagliflozin.
    Polidori D; Iijima H; Goda M; Maruyama N; Inagaki N; Crawford PA
    Diabetes Obes Metab; 2018 May; 20(5):1321-1326. PubMed ID: 29341404
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Tocotrienol-Rich Vitamin E from Palm Oil (Tocovid) and Its Effects in Diabetes and Diabetic Nephropathy: A Pilot Phase II Clinical Trial.
    Tan SMQ; Chiew Y; Ahmad B; Kadir KA
    Nutrients; 2018 Sep; 10(9):. PubMed ID: 30227659
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Fanconi syndrome associated with SGLT2 inhibitor, canagliflozin.
    Esprit DH; Koratala A
    Nephrology (Carlton); 2018 May; 23(5):493. PubMed ID: 29696765
    [No Abstract]   [Full Text] [Related]  

  • 72. The effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on mineral metabolism and bone in patients with type 2 diabetes mellitus.
    Alba M; Xie J; Fung A; Desai M
    Curr Med Res Opin; 2016 Aug; 32(8):1375-85. PubMed ID: 27046479
    [TBL] [Abstract][Full Text] [Related]  

  • 73. SGLT2 Inhibition for the Prevention and Treatment of Diabetic Kidney Disease: A Review.
    Alicic RZ; Johnson EJ; Tuttle KR
    Am J Kidney Dis; 2018 Aug; 72(2):267-277. PubMed ID: 29866460
    [TBL] [Abstract][Full Text] [Related]  

  • 74. The Impact of Sotagliflozin on Renal Function, Albuminuria, Blood Pressure, and Hematocrit in Adults With Type 1 Diabetes.
    van Raalte DH; Bjornstad P; Persson F; Powell DR; de Cassia Castro R; Wang PS; Liu M; Heerspink HJL; Cherney D
    Diabetes Care; 2019 Oct; 42(10):1921-1929. PubMed ID: 31371432
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Endotrophin is a risk marker of complications in CANagliflozin cardioVascular Assessment Study (CANVAS): a randomized controlled trial.
    Rasmussen DGK; Hansen MK; Blair J; Jatkoe TA; Neal B; Karsdal MA; Genovese F
    Cardiovasc Diabetol; 2022 Nov; 21(1):261. PubMed ID: 36443792
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Insulin-Like Growth Factor Binding Protein 7 Predicts Renal and Cardiovascular Outcomes in the Canagliflozin Cardiovascular Assessment Study.
    Januzzi JL; Butler J; Sattar N; Xu J; Shaw W; Rosenthal N; Pfeifer M; Mahaffey KW; Neal B; Hansen MK
    Diabetes Care; 2021 Jan; 44(1):210-216. PubMed ID: 33158949
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Effects of canagliflozin on serum potassium in the CANagliflozin cardioVascular Assessment Study (CANVAS) Program.
    Weir MR; Slee A; Sun T; Balis D; Oh R; de Zeeuw D; Perkovic V
    Clin Kidney J; 2021 May; 14(5):1396-1402. PubMed ID: 34221371
    [TBL] [Abstract][Full Text] [Related]  

  • 78. The importance of targeting multiple risk markers in patients with type 2 diabetes: A post-hoc study from the CANVAS programme.
    Tye S; Oshima M; Arnott C; Neuen BL; Fletcher RA; Neal B; Heerspink HJL
    Diabetes Obes Metab; 2023 Jun; 25(6):1638-1645. PubMed ID: 36782264
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Canagliflozin: increased risk of toe amputations? Do not use this drug in diabetes.
    Prescrire Int; 2016 Oct; 25(175):243. PubMed ID: 30645831
    [No Abstract]   [Full Text] [Related]  

  • 80. Are SGLT2 Inhibitors Safe and Effective in Advanced Diabetic Kidney Disease?
    Zoungas S; Polkinghorne KR
    Clin J Am Soc Nephrol; 2020 Dec; 15(12):1694-1695. PubMed ID: 33214159
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.